NCE-1 Intelligence & Market Opportunity

Hernexeos

Zongertinib

Anticancer

Oral Tablet

Hernexeos is an oral tyrosine kinase inhibitor used to treat adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Treatment is indicated following prior systemic therapy, and eligibility requires confirmation of the HER2 mutation via an FDA-approved test.

Approval Date

08-Aug-25

NCE-1 Date

08-Aug-29

NCE Date

08-Aug-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Zongertinib

Innovator

BOEHRINGER INGELHEIM PHARMACEUTICALS INC

Dosage Form

Oral Tablet

Strength

60 mg

Therapeutic Category

Anticancer

Usage

To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets